Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial

Stroke

Volumn 31, Issue 10, 2000, Pages 2335-2341

  Broderick, Joseph P ^a   Lu, Mei ^b   Kothari, Rashmi ^c   Levine, Steven R ^d   Lyden, Patrick D ^e   Haley, E Clark ^f   Brott, Thomas G ^g   Grotta, James ^h   Tilley, Barbara C ⁱ   Marler, John R ^j   Frankel, Michael ^k  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c Borgess Research Institute   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Clinical trials; Models, predictive; Outcome; Stroke; Tissue plasminogen activator

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DRUG EFFECT; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; RECANALIZATION; REGRESSION ANALYSIS; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033800679     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.10.2335     Document Type: Article

References (23)

1. Tissue plasminogen activator for acute ischemic stroke
2. Assessment scales for the evaluation of stroke patients
3. Interobserver agreement for the assessment of handicap in stroke patients
4. Measurements of acute cerebral infarction: A clinical examination scale
5. Assessment of outcome after severe brain injury: A practical scale
6. Functional evaluation: The Barthel index
7. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Study Trial
8. Effect of intravenous rt-PA on ischemic stroke lesion size measured by computed tomography
9. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial
10. Underlying structure of the National Institutes of Health Stroke Scale: Results of a factor analysis
11. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
12. Improved reliability of the NIH Stroke Scale using video training
13. Urgent therapy for stroke: Pilot study of tissue pIasminogen activator administered within 90 minutes
14. Dichotomized efficacy endpoints and global endpoint analysis applied to the ECASS intention-to-treat data set: Post hoc analysis of ECASS I
15. Randomised, double-blind, placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II)
16. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II Study: A randomized controlled trial
17. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial
18. Multinational randomized controlled trial of lubeluzole in acute ischaemic stroke: European and Australian Lubeluzole Ischaemic Stroke Study Group
19. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
20. Pitfalls and potential of clinical diffusion-weighted MR imaging in acute stroke
21. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI
22. Expanding the window for thrombolytic therapy in acute stroke: The potential role of acute MRI for patient selection